# 14C-ARN-509 Microtracer Label AME and Absolute BA Study

> **NCT01822041** · PHASE1 · COMPLETED · sponsor: **Aragon Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ARN-509

## Key facts

- **NCT ID:** NCT01822041
- **Lead sponsor:** Aragon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822041, "14C-ARN-509 Microtracer Label AME and Absolute BA Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01822041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*